November 14th, 2006
Rehovot, Israel – November 14th, 2006 – Evogene Ltd. announced today the establishment of Evogene Inc. as a subsidiary based in Boston, MA.
The initial role for the subsidiary will be to co-ordinate Evogene’s activities in North America with its licensees, with the expectation that in the future it would also manage field trials for Evogene products.
Ofer Haviv, Evogene’s CEO stated: “The North American market is the leading market in the field of agro-biotechnology both in terms of market share and the development of new improved crops. Essentially all major agbio companies are either located there or have substantial operations. For that reason we felt that it was essential for us to establish a presence to meet the needs of our current and future partners".
About Evogene
Evogene’s mission is to be a world leader in delivering improved plant traits to the agro-biotechnology industry through the use of a continuously improving proprietary platform combining state-of-the-art computational genomics, molecular biology and advanced breeding methods. Evogene’s current product development portfolio includes such traits as: abiotic stress tolerance and yield, enhancement of cotton fiber quality, improving nitrogen use efficiency, increasing oil yield for the BioDiesel industry and plant manufacturing of therapeutic proteins. Until its spin-off as a separate company in 2002, Evogene was the agro-biotechnology division of Compugen Ltd. (Nasdaq: CGEN). Evogene’s core in-silico technology, the ATHLETE, was built on Compugen’s proprietary LEADS platform and it maintains a license for its use in the agro-biotechnology field.
Contact Information:
Evogene
Ofer Haviv
Chief Executive Officer
E-mail: ofer.haviv@evogene.com
Tel: +972 8 931 1904
print page |
